Your search returned 2 results.

Results
	1.	Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus. [electronic resource] by Reilly, Timothy P Graziano, Michael J Janovitz, Evan B Dorr, Thomas E Fairchild, Craig Lee, Francis Chen, Jian Wong, Tai Whaley, Jean M Tirmenstein, Mark Producer: 20140622 In: Diabetes therapy : research, treatment and education of diabetes and related disorders vol. 5 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Nonclinical toxicology assessments support the chronic safety of dapagliflozin, a first-in-class sodium-glucose cotransporter 2 inhibitor. [electronic resource] by Tirmenstein, Mark Dorr, Thomas E Janovitz, Evan B Hagan, Deborah Abell, Lynn M Onorato, Joelle M Whaley, Jean M Graziano, Michael J Reilly, Timothy P Producer: 20140610 In: International journal of toxicology vol. 32 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)

Refine your search